The BD Veritor™ Plus System
The BD Veritor™ Plus System offers point-of-care testing with SARS-CoV-2*, Flu A+B, RSV (respiratory syncytial virus), and Group A Strep assays – providing rapid diagnostic testing in a convenient, portable instrument.
Interpreting test results
Giving you a clear view
Reliable results are important to help you to confidently create treatment plans that fit your patients’ needs. The BD Veritor™ Plus System provides rapid, reliable results to provide you the information you need to determine appropriate treatment plans for your patients quickly and efficiently.
Key topics related to diagnostic testing are explained below; you will find more information in our resource library.
Interpreting diagnostic test results
Timely and reliable results from rapid antigen testing allow caregivers to more quickly determine appropriate treatment plans. The BD Veritor™ Plus System provides rapid, reliable results that are easy to interpret – which can help give peace of mind to you and your patients in 15 minutes or less1-6.
Understanding clinical performance
You’ve performed the test, now it’s time to understand the results. While unusual, false positive results are a possible outcome in any diagnostic test. In the case of antigen tests, results could be influenced by workflow inconsistencies, quality of the sample itself, or protocol failure, to name a few.
When testing for SARS-CoV-2 in particular, It is important to understand how local disease prevalence rate and test performance characteristics may interact to influence the proportion of false positive test results compared to all positive results. The infographic below demonstrates how very low, low, medium and high prevalence rates make a difference. It is important to note that your institution’s specific prevalence rates can be used to calculate the potential for false positives in your facility. Understanding that false positive test results are a possibility is important. Please follow your institution and/or state and local guidance for addressing a patient with a positive test result. Guidance may include precautionary isolation procedures and a second mode of testing for confirmation.
SARS-CoV-2 hypothetical false positive rates based on prevalence¹
Note: we are using a figure of 99.5% specificity in these calculations. The PPV values reflect this calculation and are within the stated confidence intervals stated in the Instructions for Use.
Learn more about clinical questions related to COVID-19, including false positives
False positives based on prevalence
The BD Veritor™ System for Rapid Detection of SARS-CoV-2 has a 98%-100% specificity, which means the false positive rate 2% or less of all the tests performed1. This means, you might see 0-2 false positives for every 100 tests you conduct. Any false positive should be reported to BD for further investigation.
BD Veritor™ Plus System makes it easy to perform accurate tests. Find educational resources here.
For CDC information on prevalence rates:
CDC offers guidance for rapid antigen testing: